ABT-888 (Veliparib): Potent PARP1/2 Inhibitor for DNA Repair Inhibition

Executive Summary: ABT-888 (Veliparib) is a selective inhibitor of PARP1 (Ki = 5.2 nM) and PARP2 (Ki = 2.9 nM), disrupting DNA repair in tumor cells (APExBIO; product page). This compound sensitizes microsatellite instability (MSI) tumor models, especially those with MRE11 or RAD50 mutations, to chemotherapy and radiation. ABT-888 is highly effective in preclinical colorectal cancer xenografts, enhancing activity and delaying tumor growth when combined with SN38 or oxaliplatin (Pettenger-Willey et al. 2025). The compound is insoluble in water, but soluble in ethanol and DMSO; storage at -20°C is recommended for both solid and solution forms. ABT-888 purity exceeds 99.5% by HPLC and NMR analyses (APExBIO).

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes, notably PARP1 and PARP2, are central to the cellular response to DNA damage. These enzymes facilitate the repair of single-strand DNA breaks via the base excision repair (BER) pathway. Inhibition of PARP activity leads to accumulation of unrepaired DNA damage, culminating in cell death, particularly in tumor cells with deficient homologous recombination repair mechanisms, such as those with microsatellite instability (MSI) or mutations in DNA repair genes (e.g., MRE11, RAD50) (Pettenger-Willey et al. 2025). Targeting the PARP-mediated DNA repair pathway is a validated strategy for sensitizing cancer cells to cytotoxic chemotherapy and radiation. ABT-888 (Veliparib), supplied by APExBIO, exemplifies this approach by delivering potent, selective inhibition of PARP enzymes (product page).

Mechanism of Action of ABT-888 (Veliparib)

ABT-888 (Veliparib) binds the catalytic domain of PARP1 and PARP2, with inhibition constants (Ki) of 5.2 nM and 2.9 nM, respectively. This binding blocks poly (ADP-ribose) chain formation and halts recruitment of DNA repair factors to sites of single-strand breaks. In cells with defective homologous recombination (e.g., BRCA1/2, MRE11, RAD50 mutations or MSI phenotype), this results in persistent DNA lesions and synthetic lethality. The compound’s effect is most pronounced in tumor models exhibiting DNA repair deficiencies and is synergistic with DNA-damaging agents such as SN38 and oxaliplatin (doi). ABT-888 does not directly induce DNA breaks but impairs cellular recovery from genotoxic stress, enhancing apoptosis via the caspase signaling pathway (ABT-888: Redefining PARP Inhibition).

Evidence & Benchmarks

• ABT-888 inhibits PARP1 and PARP2 with Ki values of 5.2 nM and 2.9 nM, respectively, as determined by in vitro enzymatic assays (APExBIO).
• In vivo, ABT-888 sensitizes colorectal cancer xenograft models to SN38 and oxaliplatin, significantly delaying tumor growth (Pettenger-Willey et al. 2025, doi).
• Cell lines with microsatellite instability (MSI) and defective MRE11 or RAD50 show increased responsiveness to PARP inhibition by ABT-888 (ABT-888: Unraveling PARP Inhibition).
• ABT-888 displays high purity (>99.5%) by HPLC and NMR under standard QC protocols (APExBIO).
• PARP inhibition by ABT-888 does not increase calicheamicin-induced cytotoxicity in acute leukemia cell lines, suggesting pathway specificity (Pettenger-Willey et al. 2025, doi).

This article extends prior coverage (ABT-888: Potent PARP1/2 Inhibitor for DNA Repair Sensitization) by detailing new evidence from 2025 studies and clarifying parameters for workflow integration. It also updates mechanistic insights presented in ABT-888: Advanced PARP Inhibition for MSI Tumor Models with benchmarked in vivo outcomes.

Applications, Limits & Misconceptions

ABT-888 is used in preclinical cancer research to sensitize tumor cells to chemotherapeutics and radiation, especially in models with impaired DNA repair. It is valuable for dissecting the DNA damage response pathway, benchmarking the effects of PARP inhibition, and exploring synthetic lethality in MSI or homologous recombination-deficient (HRD) contexts. However, its utility is limited in settings where DNA repair pathways are not compromised or where cytotoxic agents do not act via DNA damage.

Common Pitfalls or Misconceptions

• ABT-888 does not directly kill cells with intact DNA repair machinery; efficacy depends on pre-existing DNA repair deficiencies (doi).
• PARP inhibition by ABT-888 is not universally synergistic with all DNA-damaging agents; specific agents and tumor models must be validated (source).
• ABT-888 does not enhance calicheamicin-induced cytotoxicity in acute leukemia, indicating pathway-selective effects (Pettenger-Willey et al. 2025, doi).
• Long-term storage of ABT-888 solutions is not recommended; compound should be freshly prepared for experimental use (APExBIO).
• ABT-888 is supplied for research use only; it is not intended for clinical or diagnostic applications (APExBIO).

Workflow Integration & Parameters

For experimental applications, ABT-888 (A3002) is best dissolved in DMSO (≥6.11 mg/mL) or ethanol (≥10.6 mg/mL with ultrasonication). Stock solutions are typically prepared at concentrations >10 mM with warming and ultrasonic treatment to optimize solubility. The recommended storage temperature for both solid and solution forms is -20°C, with solutions used immediately or within a short duration to ensure stability. Purity is independently verified by HPLC and NMR. ABT-888 is provided by APExBIO for research use only. For comprehensive protocols and troubleshooting, refer to recent in-depth reviews (ABT-888: Redefining PARP Inhibition).

Conclusion & Outlook

ABT-888 (Veliparib) is a benchmark PARP1/2 inhibitor for dissecting DNA damage response and sensitization in cancer research. Its potency, selectivity, and validated mechanism make it a cornerstone for studies in MSI and HR-deficient tumor models, especially in combination with DNA-damaging agents. Recent evidence affirms its pathway specificity and delineates its practical utility and boundaries. Continued research will refine its applications and clarify optimal combinatorial strategies for translational oncology (Pettenger-Willey et al. 2025).